XML 66 R53.htm IDEA: XBRL DOCUMENT v3.20.2
License agreements - Agenus (Details)
$ / shares in Units, $ in Thousands, shares in Millions
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Feb. 14, 2017
USD ($)
$ / shares
Feb. 01, 2017
USD ($)
$ / shares
shares
Dec. 31, 2017
USD ($)
Feb. 28, 2017
USD ($)
Nov. 30, 2015
item
Jan. 31, 2015
USD ($)
item
Jun. 30, 2020
USD ($)
$ / shares
shares
Jun. 30, 2019
USD ($)
Jun. 30, 2020
USD ($)
$ / shares
Jun. 30, 2019
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
License agreements                          
Long term investments             $ 248,731   $ 248,731     $ 133,657  
Research and development expense             286,601 $ 289,363 1,371,888 $ 559,908      
Unrealized gain (loss) on long term investments             72,274 (4,625) 24,142 16,364      
Current assets             2,077,625   2,077,625     2,481,488  
Current liabilities             556,513   $ 556,513     513,340  
Minimum                          
License agreements                          
Royalty payments on future global net sales (as a percent)     15.00%                    
Agenus                          
License agreements                          
Number of program targets | item         3 4              
Royalty payments on future global net sales (as a percent)                 15.00%        
Upfront payment under license agreement           $ 60,000              
Period of notice for termination of license agreement       12 months                  
Agenus | Development, Regulatory and Commercialization Milestones | Minimum                          
License agreements                          
Royalty payments on future global net sales (as a percent)                 6.00%        
Agenus | Development, Regulatory and Commercialization Milestones | Maximum                          
License agreements                          
Royalty payments on future global net sales (as a percent)                 12.00%        
Additional milestone payments under the license agreement       $ 510,000                  
Agenus | Development Milestones                          
License agreements                          
Upfront payment under license agreement                     $ 20,000    
Additional milestone payments under the license agreement                         $ 5,000
Agenus                          
License agreements                          
Long term investments             65,100   $ 65,100     72,300  
Research and development expense             $ 200 500 $ 300 900      
Shares divested (in shares) | shares             1.2            
Ownership percentage (as a percent) 18.00%           9.80%   9.80%        
Gross proceeds from sale of stock             $ 4,500            
Unrealized gain (loss) on long term investments             26,200 $ 500 $ (2,700) $ 11,000      
Agenus | Accrued and other liabilities                          
License agreements                          
Accrued and other liabilities             $ 1,500   $ 1,500     $ 1,600  
Agenus | Minimum                          
License agreements                          
Share price (per share) | $ / shares             $ 3.57   $ 3.57        
Agenus | Maximum                          
License agreements                          
Share price (per share) | $ / shares             $ 4.21   $ 4.21        
Agenus | Stock purchase agreement                          
License agreements                          
Purchase of common stock under Stock Purchase Agreement (in shares ) | shares   10.0                      
Purchase price of common stock   $ 60,000                      
Per share price | $ / shares $ 4.40 $ 6.00                      
Discount for lack of marketability $ 4,500                        
Fair value of shares on the issuance date 39,500                        
Total consideration paid $ 60,000                        
Long term investments     $ 39,500               39,500    
Research and development expense                     $ 20,500